Release results from the TRANQUILITY clinical trials
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Nov 2021
- Due
- 31 Dec 2021
- Checked
- 2 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“results from the TRANQUILITY trials are expected to be released by the end of the year.”
What we found
Evidence strength A What the grades mean
The company did not release the TRANQUILITY trial results by the end of 2021; subsequent filings indicate the results were expected in mid-2022.
-
A Aldeyra Therapeutics, Inc. 8-K filed 2022-03-17
“Results from Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease Expected Mid-2022” ✓ confirmed on the page
Market reaction: the shares moved +12.3% against the S&P 500 over the three sessions around the disclosure (16 Mar 2022 to 21 Mar 2022). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Release
- Deliverable
- TRANQUILITY clinical trial results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Conditional
- Yes: Pending confirmation of statistical powering and other analyses of the Phase 2 clinical trial results
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ALDX-003450 · Corrections policy